Abstract: A computer-implemented method includes a first module of a computing system receiving application-specific data for determining utilization attributes of multiple application programs. A second module of the system receives data for determining patient archetypes. A third module of the system determines a clinical benefit of each application program based on analysis of the application-specific data. The system matches an application program with a particular patient archetype based on analysis of each patient archetype and the determined clinical benefit of the application program. The system selects a particular application program for use by a patient of a first patient group based on: i) a characteristic of the first patient group that is included in a first patient archetype; and ii) the clinical benefit of the particular application exceeding a threshold clinical benefit.

Abstract: A computer-implemented method includes a first module of a computing system receiving application-specific data for determining utilization attributes of multiple application programs. A second module of the system receives data for determining patient archetypes. A third module of the system determines a clinical benefit of each application program based on analysis of the application-specific data. The system matches an application program with a particular patient archetype based on analysis of each patient archetype and the determined clinical benefit of the application program. The system selects a particular application program for use by a patient of a first patient group based on: i) a characteristic of the first patient group that is included in a first patient archetype; and ii) the clinical benefit of the particular application exceeding a threshold clinical benefit.

Abstract: Antibodies that bind specifically to receptor for advanced glycation end products (RAGE) and RAGE-binding fragments thereof are disclosed. Also disclosed are pharmaceutical compositions comprising such anti-RAGE antibodies and RAGE-binding antibody fragments thereof, and their use for treatment of RAGE related diseases.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.

Abstract: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.